Spanish Authorities Authorize Phase 3 Trial of J&J COVID-19 Vaccine

Spain’s medicines agency officially authorized the launch of the late-stage trial of Johnson & Johnson’s COVID-19 vaccine on Wednesday morning, as the race to develop effective vaccines to prevent the virus intensifies.

Spain’s medicines agency officially authorized the launch of the late-stage trial of Johnson & Johnson’s COVID-19 vaccine on Wednesday morning, as the race to develop effective vaccines to prevent the virus intensifies.

In a statement, Spain’s AEMPS agency said that the Phase 3 trial of the two-dose vaccination will be carried out in nine different hospitals all across the country, on volunteers both with and without previous health conditions.

The agency also explained that Spanish hospitals involved in the trial will enroll volunteers as soon as possible, pointing out that 20 percent will be younger than 40, while 30 percent will be older than 60. 

Study participants will be given a first dose of either a placebo or the experimental shot called Ad26COV2, followed by a second dose or placebo later.

The Phase III trials will be carried out on 30,000 volunteers in nine different nations around the world. 

The two-dose study will run in parallel with a trial of a single shot regimen involving 60,000 participants, which was launched in September.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.